Crossmark

Haemodynamic and clinical impacts of switching phosphodiesterase-5 inhibitors to riociguat in patients with chronic thromboembolic pulmonary hypertension (CTEPH) after balloon pulmonary angioplasty (BPA) – a prospective cohort study

Crossref DOI link: https://doi.org/10.1186/s12890-025-04069-y

Published Online: 2026-01-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kam, Timothy Ho Him

Kam, Kevin Ka Ho

Wong, Michael Ka Lam

Yan, Bryan Ping Yen

Tan, Guangming
License Information

Text and Data Mining valid from 2026-01-03

Version of Record valid from 2026-02-02
More Information

Article History

Received: 2 August 2025

Accepted: 11 December 2025

First Online: 3 January 2026

Declarations

:

: This study was approved by the Joint Chinese University of Hong Kong-New Territories East Cluster Clinical Research Ethics Committee (Ref: 2023.577). Written informed consent to participate in the study was obtained from all participating patients.

: Written informed consent was obtained from all participating patients for the publication of their details.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below